See more : Dream Unlimited Corp. (DRUNF) Income Statement Analysis – Financial Results
Complete financial analysis of Pharma-Bio Serv, Inc. (PBSV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharma-Bio Serv, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Metavesco, Inc. (MVCO) Income Statement Analysis – Financial Results
- Bluestem Group Inc. (BGRP) Income Statement Analysis – Financial Results
- Gesher I Acquisition Corp. (GIACU) Income Statement Analysis – Financial Results
- Beijing Urban Construction Design & Development Group Co., Limited (1599.HK) Income Statement Analysis – Financial Results
- Befesa S.A. (BFSA.DE) Income Statement Analysis – Financial Results
Pharma-Bio Serv, Inc. (PBSV)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.pharmabioserv.com
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.98M | 19.40M | 20.12M | 21.56M | 19.51M | 17.80M | 15.58M | 19.54M | 23.38M | 27.56M | 33.06M | 29.23M | 19.93M | 11.35M | 11.48M | 15.20M | 16.20M | 14.23M | 10.00K |
| Cost of Revenue | 11.91M | 14.52M | 14.76M | 14.90M | 13.33M | 12.11M | 11.97M | 13.75M | 15.90M | 18.58M | 21.23M | 19.36M | 13.07M | 7.95M | 7.64M | 9.41M | 9.38M | 8.12M | 0.00 |
| Gross Profit | 5.07M | 4.88M | 5.36M | 6.67M | 6.18M | 5.69M | 3.61M | 5.78M | 7.48M | 8.97M | 11.83M | 9.87M | 6.86M | 3.39M | 3.84M | 5.79M | 6.82M | 6.11M | 10.00K |
| Gross Profit Ratio | 29.84% | 25.16% | 26.65% | 30.92% | 31.66% | 31.95% | 23.18% | 29.60% | 32.01% | 32.56% | 35.79% | 33.78% | 34.42% | 29.90% | 33.44% | 38.10% | 42.11% | 42.96% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.60M | 5.04M | 5.87M | 5.70M | 6.11M | 5.76M | 4.14M | 3.41M | 2.78M | 2.92M | 3.14M | 3.18M | 2.03M | 40.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.95M | 3.71M | 9.21M | 4.44M | 4.48M | 4.60M | 5.04M | 5.87M | 5.70M | 6.11M | 5.76M | 4.14M | 3.41M | 2.78M | 2.92M | 3.14M | 3.18M | 2.03M | 40.00K |
| Other Expenses | 0.00 | 13.42K | 1.98M | 64.46K | 526.57K | 435.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 194.98K | 0.00 |
| Operating Expenses | 3.95M | 3.71M | 9.21M | 4.44M | 4.48M | 4.60M | 5.04M | 5.87M | 5.70M | 6.11M | 5.76M | 4.14M | 3.41M | 2.78M | 2.92M | 3.14M | 3.18M | 2.23M | 40.00K |
| Cost & Expenses | 15.86M | 18.22M | 23.97M | 19.34M | 17.81M | 16.71M | 17.00M | 19.63M | 21.60M | 24.69M | 26.99M | 23.49M | 16.48M | 10.74M | 10.56M | 12.54M | 12.56M | 10.34M | 40.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.81K | 5.35K | 10.33K | 11.08K | 19.71K | 14.98K | 26.96K | 82.71M | 107.51M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 223.96K | 7.34K | 7.19K | 7.21K | 7.43K | 6.61K | 5.61K | 52.39K | 144.74K | 335.99K | 392.74K | 0.00 |
| Depreciation & Amortization | 194.32K | 51.11K | 72.73K | 86.28K | 99.10K | 74.60K | 107.68K | 312.56K | 357.46K | 377.20K | 344.52K | 321.73K | 320.86K | 321.71K | 307.33K | 227.15K | 208.23K | 194.98K | 0.00 |
| EBITDA | 1.31M | 1.23M | -3.78M | 2.31M | 1.80M | 1.16M | -710.02K | 220.80K | 2.16M | 3.24M | 6.42M | 6.08M | 3.79M | 948.51K | 1.26M | 2.96M | 3.86M | 4.08M | -20.00K |
| EBITDA Ratio | 7.73% | 6.32% | -18.80% | 10.72% | 9.21% | 6.53% | -6.39% | 1.70% | 9.23% | 11.78% | 19.44% | 20.76% | 19.03% | 8.34% | 10.89% | 18.96% | 23.95% | 28.69% | -200.00% |
| Operating Income | 1.12M | 1.17M | -3.85M | 2.23M | 1.70M | 1.09M | -1.43M | -91.76K | 1.78M | 2.86M | 6.07M | 5.73M | 3.45M | 609.89K | 915.46K | 2.65M | 3.65M | 3.89M | -20.00K |
| Operating Income Ratio | 6.58% | 6.06% | -19.16% | 10.32% | 8.70% | 6.11% | -9.15% | -0.47% | 7.62% | 10.39% | 18.36% | 19.62% | 17.32% | 5.38% | 7.97% | 17.46% | 22.51% | 27.32% | -200.00% |
| Total Other Income/Expenses | 570.08K | 13.42K | 1.98M | 64.46K | 526.57K | 435.53K | 43.75K | -111.98K | 11.46K | 14.02K | 4.60K | 22.00K | 11.78K | 11.30K | -19.35K | -144.74K | -310.33K | -392.74K | 0.00 |
| Income Before Tax | 1.69M | 1.19M | -1.88M | 2.29M | 2.22M | 1.52M | -1.41M | -203.74K | 1.79M | 2.88M | 6.08M | 5.76M | 3.46M | 621.19K | 896.10K | 2.51M | 3.34M | 3.50M | -20.00K |
| Income Before Tax Ratio | 9.94% | 6.13% | -9.33% | 10.62% | 11.40% | 8.56% | -9.06% | -1.04% | 7.67% | 10.45% | 18.38% | 19.69% | 17.38% | 5.47% | 7.81% | 16.51% | 20.60% | 24.56% | -200.00% |
| Income Tax Expense | 377.31K | 181.68K | 213.25K | 239.09K | 135.99K | 2.79M | 3.87K | 52.83K | 167.98K | 464.53K | 1.17M | 1.07M | 304.80K | 249.28K | 361.35K | 1.02M | 1.44M | 1.16M | 0.00 |
| Net Income | 1.31M | 1.01M | -2.09M | 2.05M | 2.09M | 1.28M | -1.41M | -256.58K | 1.62M | 2.41M | 4.91M | 4.69M | 3.16M | 371.91K | 534.76K | 1.49M | 1.90M | 2.34M | -20.00K |
| Net Income Ratio | 7.72% | 5.19% | -10.39% | 9.51% | 10.70% | 7.19% | -9.08% | -1.31% | 6.95% | 8.76% | 14.84% | 16.04% | 15.85% | 3.28% | 4.66% | 9.79% | 11.73% | 16.41% | -200.00% |
| EPS | 0.06 | 0.04 | -0.09 | 0.09 | 0.09 | 0.06 | -0.06 | -0.01 | 0.07 | 0.11 | 0.22 | 0.23 | 0.15 | 0.02 | 0.03 | 0.07 | 0.10 | 0.22 | -0.07 |
| EPS Diluted | 0.06 | 0.04 | -0.09 | 0.09 | 0.09 | 0.06 | -0.06 | -0.01 | 0.07 | 0.10 | 0.21 | 0.20 | 0.14 | 0.02 | 0.02 | 0.07 | 0.09 | 0.13 | -0.07 |
| Weighted Avg Shares Out | 22.97M | 23.00M | 23.03M | 23.00M | 23.05M | 23.08M | 23.10M | 23.02M | 23.07M | 22.98M | 22.20M | 20.76M | 20.75M | 20.75M | 20.75M | 19.97M | 19.39M | 10.51M | 270.00K |
| Weighted Avg Shares Out (Dil) | 23.00M | 23.03M | 23.03M | 23.04M | 23.11M | 23.10M | 23.10M | 23.19M | 23.40M | 23.69M | 23.66M | 22.94M | 22.55M | 22.38M | 22.32M | 22.26M | 22.17M | 17.88M | 270.00K |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2021
DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic,...
Pharma-Bio Serv Announces Appointment of Kirk Michel as Chairman of the Board of Directors and Announces Special Dividend
DORADO, PUERTO RICO / ACCESSWIRE / January 5, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic,...
Source: https://incomestatements.info
Category: Stock Reports